Description
KLOW
KLOW is a Xentides four-peptide research blend combining GHK-Cu, BPC-157, TB-500, and KPV in one lyophilized vial (80 mg total). Components and nominal amounts are as declared on the label; the ratio is fixed at manufacture. Confirm each component against the certificate of analysis for your lot.
Specification
| Material | KLOW |
|---|---|
| GHK-Cu | 50 mg — Gly-His-Lys copper(II) complex, C14H23CuN6O4 (approx. 402.9 g/mol) |
| BPC-157 | 10 mg — GEPPPGKPADDAGLV, C62H98N16O22 (1419.5 g/mol) |
| TB-500 | 10 mg — synthetic peptide related to thymosin beta-4 (sequence per lot specification) |
| KPV | 10 mg — Lys-Pro-Val, C16H30N4O4 (342.4 g/mol) |
| Total peptide | 80 mg (50 + 10 + 10 + 10) |
| Amount per vial | 80 mg |
| Purity / analysis | Reported per lot on the certificate of analysis, when published |
| Form | Lyophilized powder in a sealed vial (confirm on label) |
Storage and handling
Store sealed vials cold (2–8 °C for short-term, −20 °C for longer-term storage), dry, and protected from light, unless the label states otherwise. Allow vials to reach room temperature before opening to limit moisture uptake. Handle according to your laboratory’s procedures.
Certificate of analysis
Each lot is identified on its label. When a certificate of analysis is published for a lot, it appears in Lab reports under that lot identifier, naming the testing laboratory and the methods used. Before ordering, match the product name, amount, and lot identifier on the label against available documentation in Lab reports. Lot documentation is being published; if a report for your lot is not listed, email info@xentides.com with the product and lot.
For laboratory research only. Not for human or veterinary use, consumption, clinical treatment, or self-experimentation. Not evaluated or approved by the FDA. Xentides provides no dosing, administration, or medical advice.
